Higher opex leads to EBITDAPAT miss

03 May 2024
5 Min read 
  • Ajanta Pharma's 4QFY24 results update includes changes in estimates, target price, and rating.
  •  The company aims to consistently outperform the industry in branded generics.
  •  Despite in-line sales, EBITDA/PAT missed expectations due to higher opex.
  •  The company plans to file 8-12 ANDAs and launch 6 ANDAs in US generics in FY25.
  •  Ajanta Pharma's revenue grew 20% in 4QFY24, with growth across all key business segments.
  •  The company expects low-teens YoY growth in revenue for FY25.
Login / Open Demat Account to read the report

Never Miss Out on Hot Market Updates

Get exclusive market news delivered to your inbox - on priority